Researchers identify gene signature for high-risk form of T-cell acute lymphoblastic leukemia
Researchers from Children's Hospital of Philadelphia (CHOP) have discovered the underlying biology that identifies a subset of patients with acute lymphoblastic leukemia who have a higher risk version of the disease and are more likely to relapse despite treatment. The findings have allowed researchers to identify new potential therapeutic treatments for patients with this specific form of cancer with a high risk of recurrence.
Comments